PTC Therapeutics (NASDAQ:PTCT) VP Sells $1,382,504.00 in Stock

Key Points

• PTC Therapeutics VP Mark Elliott Boulding sold 22,664 shares at an average price of $61.00, totaling $1,382,504.00, reducing his stake by 17.91% to 103,901 shares.
• The company's stock price recently dipped to $59.00, with a market capitalization of $4.69 billion and a 1-year trading range between $33.58 and $62.18.
• In its latest earnings report, PTC Therapeutics surpassed EPS expectations with a reported loss of ($0.83), while revenue declined 4.2% year-over-year to $178.88 million.

PTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) VP Mark Elliott Boulding sold 22,664 shares of the company's stock in a transaction dated Thursday, September 11th. The stock was sold at an average price of $61.00, for a total value of $1,382,504.00. Following the sale, the vice president owned 103,901 shares of the company's stock, valued at approximately $6,337,961. This trade represents a 17.91% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Mark Elliott Boulding also recently made the following trade(s):

• On Friday, September 12th, Mark Elliott Boulding sold 24,585 shares of PTC Therapeutics stock. The stock was sold at an average price of $61.34, for a total value of $1,508,043.90.

PTC Therapeutics Price Performance

Shares of NASDAQ PTCT traded down $2.09 during trading hours on Monday, hitting $59.00. 1,300,729 shares of the company's stock were exchanged, compared to its average volume of 1,104,518. PTC Therapeutics, Inc. has a 1-year low of $33.58 and a 1-year high of $62.18. The stock has a market capitalization of $4.69 billion, a price-to-earnings ratio of 8.46 and a beta of 0.53. The company's 50-day moving average price is $50.27 and its 200-day moving average price is $49.47.

PTC Therapeutics (NASDAQ:PTCT - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported ($0.83) earnings per share for the quarter, topping the consensus estimate of ($1.07) by $0.24. PTC Therapeutics had a negative return on equity of 106.31% and a net margin of 35.65%.The business had revenue of $178.88 million during the quarter, compared to analysts' expectations of $173.01 million. During the same quarter in the previous year, the firm earned ($1.29) EPS. The firm's revenue was down 4.2% compared to the same quarter last year. PTC Therapeutics has set its FY 2025 guidance at EPS. On average, research analysts expect that PTC Therapeutics, Inc. will post -4.52 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on PTCT shares. UBS Group boosted their price objective on PTC Therapeutics from $71.00 to $80.00 and gave the stock a "buy" rating in a research report on Tuesday, July 29th. Barclays boosted their price objective on PTC Therapeutics from $42.00 to $46.00 and gave the stock an "equal weight" rating in a research report on Tuesday, July 29th. Cantor Fitzgerald restated an "overweight" rating and set a $118.00 price target on shares of PTC Therapeutics in a research note on Wednesday, September 3rd. Truist Financial boosted their price target on PTC Therapeutics from $80.00 to $86.00 and gave the company a "buy" rating in a research note on Tuesday, July 29th. Finally, Citigroup boosted their price target on PTC Therapeutics from $40.00 to $50.00 and gave the company a "neutral" rating in a research note on Monday, July 28th. Nine research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $69.00.

Institutional Investors Weigh In On PTC Therapeutics

Several large investors have recently modified their holdings of PTCT. Deutsche Bank AG grew its stake in shares of PTC Therapeutics by 92.3% in the 4th quarter. Deutsche Bank AG now owns 94,378 shares of the biopharmaceutical company's stock valued at $4,260,000 after purchasing an additional 45,310 shares during the period. Lazard Asset Management LLC grew its stake in shares of PTC Therapeutics by 294.3% in the 4th quarter. Lazard Asset Management LLC now owns 45,647 shares of the biopharmaceutical company's stock valued at $2,059,000 after purchasing an additional 34,069 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of PTC Therapeutics by 0.3% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 65,681 shares of the biopharmaceutical company's stock valued at $2,967,000 after purchasing an additional 205 shares during the period. Millennium Management LLC grew its position in PTC Therapeutics by 41.0% during the 4th quarter. Millennium Management LLC now owns 309,423 shares of the biopharmaceutical company's stock worth $13,967,000 after acquiring an additional 89,959 shares during the last quarter. Finally, Nuveen Asset Management LLC grew its position in PTC Therapeutics by 34.0% during the 4th quarter. Nuveen Asset Management LLC now owns 1,077,794 shares of the biopharmaceutical company's stock worth $48,652,000 after acquiring an additional 273,638 shares during the last quarter.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.